In this episode, David interviews Sherry Rais: Executive Director of the Boston Psychedelic Research Group, Grants Manager for CIIS, and CEO/Co-Founder of Enthea. Enthea is a benefit plan administrator that provides health plan benefit riders and single case agreement services for psychedelic healthcare with a provider network including certified and credentialed Ketamine-Assisted Therapy (KAT) and […]

The post PT376 – Ketamine and Psychedelic-Assisted Therapy as Employee Benefits appeared first on Psychedelics Today.

Previous articlePsychedelic Bulletin #125: New Data Boosts Spravato’s Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas
Next articleAbuse Potential: Considerations for Rescheduling MDMA and Psychedelics